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ABSTRACT
Objectives To describe the prevalence of medication
use to assist sexual performance in Britain and to
identify associated factors.
Methods Cross-sectional probability sample,
undertaken in 2010–2012, of 15 162 people aged
16–74 years, resident in Britain, of whom, 5617 men
and 8095 women reported sexual experience (ever) and
4817 men were sexually-active (reported sex in the
last year).
Results Ever use of medication to assist sexual
performance (medicated sex) was more commonly
reported by men than women (12.9% (95% CI 11.9%
to 13.9%) vs 1.9% (95% CI 1.7% to 2.3%)) and
associated with older age in men and younger age in
women. It was associated with reporting smoking, and
use of alcohol and recreational drugs, as well as unsafe
sex (≥2 partners and no condom use in the last year) in
both men and women. Among men, the proportion
reporting medicated sex in the last year was higher
among those reporting erectile difﬁculties (ED) than
those not doing so (28.4% (95% CI 24.4% to 32.8%)
vs 4.1% (95% CI 3.4% to 4.9%)). In all men,
medicated sex was associated with more frequent sexual
activity, meeting a partner on the internet, unsafe sex
and recent sexually transmitted infections diagnosis;
associations that persisted after adjusting for same-sex
behaviour and ED. However, there were signiﬁcant
interactions with reporting ED, indicating that among
men with ED, medicated sex is not associated with
same-sex behaviour and ever use of recreational drugs.
Conclusions A substantial minority of people in Britain
report medicated sex, and the association between
medicated sex and risky sexual behaviour is not conﬁned
to high-risk groups.
INTRODUCTION
In recent years, there has been a proliferation of
medication for sexual performance. Foremost are
phospodiesteraise type 5 (PDE-5) inhibitors, which
have revolutionised treatment of erectile difﬁculties
(ED); Viagra (sildenaﬁl citrate), in particular, has
become a metaphor for male sexual prowess.1 Less
well-known options for men include testosterone
for low desire and selective serotonin reuptake inhi-
bitors for early ejaculation. Medication for women
mostly focuses on low sexual desire, and is limited
in comparison. Prescribing of testosterone for
women is highly restricted, and several drugs have
recently failed to secure regulatory approval
because their marginal beneﬁts are outweighed by
signiﬁcant risk.2 Recreational drugs such as crystal
methamphetamine are also used to facilitate arousal
and promote more adventurous sexual activity,3 4
often in combination with PDE-5 inhibitors.5–7
Use of medication may be formal or informal.
Formal use implies treatment for a diagnosed
sexual function problem under the care of a health
professional, while the latter implies self-accessed
medication or recreational drugs or off-label use of
prescribed drugs, taken primarily to enhance sexual
experiences. The informal use of pharmacological
aids to sexual performance raises three concerns.1 8
First, in speciﬁc population groups—including men
who have sex with men (MSM),4 9–11 undergradu-
ate students,7 men entering HIV care12 and male
sexually transmitted infections (STI) clinic atten-
dees13—sildenaﬁl citrate use is associated with
unsafe sex and risk-related behaviours. Second,
there are worries about potential iatrogenic effects,
including harmful drug interactions between PDE-5
inhibitors and protease inhibitors and nitrates,10 14
and erosion of conﬁdence in ability to achieve an
erection, creating psychological dependence.15
Third, where medication is accessed informally,
there is no professional consultation to rule out
contraindications or to ensure immediate and long-
term safety for the individual. There is also a
missed opportunity to talk to patients about their
perceived need for medication, to discuss the impli-
cations for their partner16 and to consider possible
alternative treatment options. As medications
become easier to access without prescription, these
issues are increasingly important. Formal use is of
concern where treatment failure exacerbates low
self-esteem caused by sexual dysfunction17 and
where adverse side effects or health risks outweigh
the beneﬁts of use. Qualitative research suggests the
possibility of signiﬁcant drawbacks for partners and
relationships; for instance, in reducing spontaneity
and in creating pressure to have sex once an expen-
sive pill has been taken.16 A number of vocal critics
of the medicated sex phenomenon18–20 have
argued that the increasing medicalisation of sex
engendered by lifestyle drugs contributes to dissat-
isfaction with other than ‘perfect’ sex.21
Despite these signiﬁcant concerns, little is under-
stood about the phenomenon of medicated sex at a
population level. The existing data are limited
and come almost exclusively from convenience
studies of speciﬁc population groups, particularly
MSM.4 9 10 22 23 Such studies cannot tell us about
the scale of use in the population as a whole, or
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whether associations with risk behaviour and low sexual func-
tion are conﬁned to speciﬁc groups or apply more generally.
Here, we use data from a national probability sample, the
third National Survey of Sexual Attitudes and Lifestyles
(Natsal-3) to describe the use of any type of medication to assist
sexual performance in the British population. We hypothesised
that because of the relative lack of efﬁcacious medication for
women, more men than women would report medication use.
We also hypothesised that, because of the salience and efﬁcacy
of PDE-5 inhibitors relative to other medication, men with ED
would be more likely to use medication than those without, and
the two groups would differ in terms of their health and level
of sexual desire. Finally, we sought to determine whether asso-
ciations between medication use and high levels of sexual behav-
iour and risk, same-sex sex and use of recreational drugs
established by studies of high-risk groups, would also be
observed at a population level.
METHODS
Participants and procedure
Natsal-3 is a stratiﬁed probability sample survey of 6293 men
and 8869 women aged 16–74 years, resident in Britain. The
overall response rate was 57.7%, and the cooperation rate was
65.8% (of all eligible addresses contacted). Interviews were
carried out between September 2010 and August 2012.
Participants were interviewed using computer-assisted personal
interviewing with computer-assisted self-interview (CASI) for
the more sensitive questions. Details of the methods have been
published previously.24 Natsal-3 was approved by the National
Research Ethics Service Committee South Central—Oxford A
(Ref: 10/H0604/27). Participants provided oral informed
consent for interviews.
Outcome measures
We asked sexually experienced participants—deﬁned as those
who reported ever having at least one sexual partner—about
their use of medication to assist their sexual performance in the
self-completion component of the questionnaire. The question
was worded: ‘have you ever taken any type of medicine or pills
to assist your sexual performance, for example Viagra? Include
medication that has not been prescribed by a doctor’. Those
who responded ‘yes’ were asked to report when they had last
done so. Use of medication to assist sexual performance ever,
and in the last year, was the primary outcome.
Statistical analysis
We undertook all analyses using the complex survey functions
of STATAV.12(Stata, College Station, Texas, USA) to incorporate
the weighting, clustering and stratiﬁcation of data. We present
data on ever use among sexually experienced women and men.
Analysis of medication use in the last year was restricted to sexu-
ally active men (deﬁned as those reporting at least one sexual
partner in the last year); the same analysis was not possible for
women due to small numbers.
We used binary logistic regression to calculate ORs, adjusted
for age, to examine the relationship between reporting medica-
tion use in the last year and a wide range of variables. To
explore sociodemographic, health and sexual function variables,
we investigated the use of medication separately among men
who did and did not report ED in the last year. Men were asked
if they had experienced any of a range of sexual problems for at
least 3 months in the last year and those who endorsed the item
‘had trouble getting or keeping an erection’ were categorised as
reporting ED in the last year. To understand how medication
use varies with sexual lifestyles and behaviour, we explored
associations between medication use and key sexual behaviour
variables for all men, adjusting ﬁrst for age, second for age and
same-sex sex and third for age, same-sex sex and reporting ED.
Item non-response was low (typically <3%).
RESULTS
Medicated sex ever among sexually experienced men
and women
Table 1 shows the proportion of men and reporting medicated
sex ever, and factors associated with ever use. Among those
sexually experienced (6863 men and 7067 women), ever use of
medication was more commonly reported by men (12.9%, 95%
CI 11.9% to 13.9%) than by women (1.9%, 95% CI 1.7% to
2.3%). We found opposite patterns of use by age; an association
with older age in men and younger age in women (OR for
55–74 age group compared with 16–34 age group: 2.31 (95%
CI 1.87 to 2.84) for men and 0.38 (95% CI 0.23 to 0.63) for
women, p<0.001). In both men and women, medicated sex was
signiﬁcantly associated with relationship status. In men, after
adjustment for age, medicated sex was associated with being in
a steady relationship (but not living together) and with being
previously in a live-in relationship. Among women, after adjust-
ment for age, we found that medication use was less likely
among single women, compared with those living with a
partner. In both men and women, ever use of medication was
associated with a range of health and lifestyle factors. We found
associations with cigarette smoking, drinking more than 6–8
units of alcohol weekly and ever taking recreational drugs. In
both genders, ever use of medication was associated with low
overall sexual function in the last year. There was an association
with reporting higher number of lifetime partners and with
unsafe sex (reporting two or more partners, but no condom use
in the last year), but these were stronger for men than for
women (OR for unsafe sex 3.73 (95% CI 2.87 to 4.85) for men
and 1.71 for women (95% CI 1.12 to 2.63), p<0.001). Finally,
in both genders, reporting ever using medication was associated
with having had a same-sex sexual experience.
Medicated sex in the last year among sexually active men
Table 2 shows associations between reporting medicated sex in
the last year and demographic variables, health status, sexual
function and help-seeking among men with and without ED in
the last year.
Overall, 7.2% of men reported medicated sex in the last year.
It was more frequently reported by men with ED (28.4%) com-
pared with those without (4.1%). However, because only 13%
of men reported ED in the last year (data not shown), at the
population level, approximately 50% of medicated sex occurs
among those without ED.
The prevalence of medicated sex in the last year increased
with age in both groups of men. There was no association with
partnership status in the ED group, but some evidence of an
association in the group without ED; after adjustment for age,
medication use in this latter group was less likely in those living
with a partner. We found no association in either group with
educational level or socioeconomic classiﬁcation or with ethni-
city or religious afﬁliation (data not shown).
In men with ED, as well as men without, we found no associ-
ation between medication use and overall self-reported health,
but a positive association with reporting a health condition that
had affected sexual activity in the last year. Lack of interest in
sex was associated with medication use, but only in men
without ED (OR 1.87 (1.20 to 2.93)). For men with ED,
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Table 1 Prevalence of, and factors associated with, reporting ever use of medication to assist sexual performance by gender
Men Women
% reporting
medication use 95% CI
Age-adjusted OR
(95% CI)
Denominator:
unweighted, weighted
% reporting
medication use 95% CI
Age-adjusted OR
(95% CI)
Denominator:
unweighted, weighted
Overall 12.9 (11.9 to 13.9) 5617, 6863 1.9 (1.7 to 2.3) 8095, 7067
Age group
16–34 9.2 (8.0 to 10.5) 1.00 2806, 2290 3.1 (2.6 to 3.8) 1.00 4092, 2269
35–54 11.8 (10.1 to 13.7) 1.32 (1.05 to 1.65) 1528, 2716 1.5 (1.1 to 2.1) 0.48 (0.32 to 0.71) 2235, 2774
55–74 18.9 (16.7 to 21.4) 2.31 (1.87 to 2.84) 1283, 1856 1.2 (0.8 to 1.9) 0.38 (0.23 to 0.63) 1768, 2023
Current relationship
Living with a partner 12.5 (11.2 to 13.9) 1.00 2940, 4658 1.9 (1.6 to 2.4) 1.00 4356, 4673
In a steady relationship (but
not living together)
13.9 (11.7 to 16.4) 1.66 (1.29 to 2.13) 955, 766 2.3 (1.5 to 3.4) 0.72 (0.44 to 1.18) 1373, 796
Previously in a live-in
partnership
17.3 (14.5 to 20.5) 1.41 (1.10 to 1.81) 795, 708 2.1 (1.5 to 2.9) 1.25 (0.83 to 1.90) 1620, 1153
Not in a steady relationship 9.9 (7.6 to 12.8) 1.29 (0.91 to 1.81) 920, 725 1.1 (0.6 to 2.0) 0.31 (0.16 to 0.60) 738, 439
Smoke cigarettes nowadays
No 11.9 (10.7 to 13.1) 1.00 3904, 5009 1.6 (1.3 to 1.9) 1.00 5803, 5355
Yes 15.5 (13.6 to 17.6) 1.60 (1.32 to 1.93) 1713, 1854 3.1 (2.5 to 4.0) 1.80 (1.30 to 2.50) 2292, 1711
Drink more than 6/8 units weekly
No 12.3 (11.1 to 13.6) 1.00 4029, 5042 1.8 (1.5 to 2.2) 1.00 6273, 5543
Yes 15.9 (13.8 to 18.3) 1.47 (1.20 to 1.81) 1225, 1389 3.7 (2.6 to 5.1) 1.90 (1.27 to 2.85) 943, 772
Ever taken recreational drugs (not injected)
No 10.6% (9.5% to 11.9%) 1.00 3166, 4181 1.5 (1.2% to 1.9%) 1.00 5549, 5202
Yes 16.3% (14.7% to 18.2%) 2.52 (2.07 to 3.07) 2445, 2677 3.1 (2.5% to 3.8%) 1.59 (1.14 to 2.22) 2542, 1862
Sexual function score in lowest quintile in the last year*
No 10.5 (9.5 to 11.7) 1.00 3912, 4791 1.8 (1.5 to 2.2) 1.00 5465, 4628
Yes 22.9 (19.9 to 26.2) 2.33 (1.87 to 2.90) 937, 1199 3.5 (2.6 to 4.8) 2.20 (1.52 to 3.20) 1231, 1158
Number of sexual partners, ever
1 6.0 (4.4 to 8.3) 1.00 765, 952 1.5 (1.0 to 2.4) 1.00 1606, 1613
2 6.6 (4.3 to 9.8) 1.14 (0.65 to 2.00) 478, 582 2.1 (1.2 to 3.5) 1.32 (0.64 to 2.71) 885, 813
3–4 8.2 (6.3 to 10.5) 1.44 (0.93 to 2.23) 861, 1058 1.4 (0.9 to 2.3) 0.88 (0.45 to 1.71) 1545, 1369
5–9 12.4 (10.5 to 14.5) 2.34 (1.58 to 3.45) 1391, 1718 1.2 (0.8 to 1.8) 0.68 (0.37 to 1.24) 2039, 1714
10+ 19.2 (17.3 to 21.2) 4.06 (2.80 to 5.89) 2073, 2499 3.7 (2.9 to 4.6) 2.08 (1.27 to 3.42) 1958, 1502
2+ partners without using a condom, last year
No 11.7 (10.7 to 12.8) 1.00 4894, 6200 1.8 (1.5 to 2.2) 1.00 7378, 615
Yes 25.4 (21.4 to 29.9) 3.73 (2.87 to 4.85) 611, 540 4.4 (3.0 to 6.3) 1.71 (1.12 to 2.63) 615, 7993
Ever had a same-sex experience
No 11.9 (10.9 to 12.9) 1.00 5123, 6291 1.6 (1.3 to 1.9) 1.00 6937, 6213
Yes 23.8 (19.5 to 28.7) 2.33 (1.78 to 3.05) 494, 572 4.6 (3.4 to 6.1) 2.45 (1.69 to 3.56) 1158, 854
*Sexual function is measured by the Natsal-sexual function, which assesses problems with sexual response, sexual function in relationship context and self-appraisal of sex life.25
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Table 2 Prevalence of, and factors associated with, reported use of medication in the last year among sexually active men by reporting of erectile difficulties, no erectile difficulties and all*
Men reporting erectile difficulties Men not reporting erectile difficulties All
% reporting
medication
use 95% CI
Age-adjusted OR
(95% CI)
Denominator:
unweighted,
weighted
% reporting
medication
use 95% CI
Age-adjusted OR
(95% CI)
Denominator:
unweighted,
weighted
% reporting
medication
use 95% CI
All
28.4 (24.4 to 32.8) 586, 766 4.1 (3.4 to 4.9) 4231, 5183 7.2 (6.4 to 8.1)
Age group
16–34 13.2 (9.0 to 19.0) 1.00 208, 167 2.8 (2.2 to 3.6) 1.00 2438, 2000 3.6 (2.9 to 4.4)
35–54 31.6 (24.0 to 40.4) 3.04 (1.72 to 5.38) 152, 260 3.9 (2.8 to 5.3) 1.41 (0.93 to 2.14) 1191, 2215 6.8 (5.4 to 8.4)
55–74 33.5 (27.2 to 40.3) 3.31 (1.95 to 5.61) 226, 339 7.2 (5.4 to 9.6) 2.70 (1.81 to 4.03) 602, 967 14.0 (11.7 to 16.6)
Current relationship
Living with a partner 28.8 (23.8 to 34.4) 1.00 330, 558 4.0 (3.1 to 5.0) 1.00 2369, 3693 7.2 (6.2 to 8.4)
In a steady relationship
(but not living together)
27.5 (19.3 to 37.4) 1.52 (0.86 to 2.70) 115, 89 4.3 (3.1 to 6.0) 1.70 (1.06 to 2.74) 831, 669 7.1 (5.5 to 9.1)
Previously in a live-in
partnership
32.5 (21.3 to 46.2) 1.55 (0.79 to 3.04) 69, 63 5.9 (3.8 to 9.0) 1.73 (1.03 to 2.92) 376, 324 10.1 (7.4 to 13.7)
Not in a steady relationship 21.0 (12.2 to 33.8) 1.51 (0.68 to 3.35) 70, 55 3.5 (2.1 to 5.7) 1.90 (0.95 to 3.79) 654, 495 5.1 (3.5 to 7.3)
Health
Bad/very bad 37.6 (21.6 to 56.9) 1.00 32, 44 2.5 (0.7 to 8.5) 1.00 101, 125 11.2 (6.6 to 18.5)
Fair/good/very good 27.9 (23.8 to 32.5) 0.74 (0.32 to 1.69) 553, 720 4.1 (3.5 to 4.9) 2.22 (0.59 to 8.27) 4137, 5065 7.1 (6.2 to 8.0)
Health and/or medical condition affecting sexual activity, last year
No 20.6 (16.0 to 26.2) 1.00 332, 408 3.6 (2.9 to 4.3) 1.00 3748, 4546 4.9 (4.2 to 5.8)
Yes 37.3 (30.9 to 44.2) 2.01 (1.30 to 3.12) 254, 358 7.7 (5.5 to 10.7) 1.96 (1.32 to 2.92) 490, 644 18.1 (15.1 to 21.5)
Lacked interest in having sex for 3+ months, last year
No 30.4 (25.7 to 35.5) 1.00 437, 583 3.7 (3.0 to 4.4) 1.00 3673, 4477 6.7 (5.9 to 7.7)
Yes 22.2 (15.5 to 30.6) 0.76 (0.46 to 1.26) 149, 183 6.9 (4.7 to 10.1) 1.87 (1.20 to 2.93) 558, 706 10.0 (7.6 to 13.1)
Severe symptoms of erectile difficulties, last year
No 25.0 (20.8 to 29.7) 1.00 504, 658 6.4 (5.7 to 7.3)
Yes 48.4 (36.7 to 60.3) 2.60 (1.49 to 4.54) 81, 107 48.4 (36.7 to 60.3)
Sought professional help regarding your sex life, last year
No 14.4 (10.9 to 18.7) 1.00 430, 546 3.5 (2.9 to 4.3) 1.00 4053, 4964 4.6 (3.9 to 5.4)
Yes 63.3 (54.6 to 71.3) 9.42 (5.76 to 15.42) 156, 220 16.7 (11.3 to 23.9) 5.59 (3.46 to 9.02) 183, 222 39.8 (34.1 to 45.8)
*All participants have had at least one sexual partner in the past year.
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symptom severity was strongly associated with medication use
(OR 2.60 (1.49 to 4.54)). Seeking professional help for one’s
sex life was strongly associated with medication use in men with
and without ED (OR 9.42 (5.76 to 15.42)) for men with ED
and OR 5.59 (3.46 to 9.02)) for men without ED).
Nonetheless, among men with ED, 14.4% of those who had
not sought professional help in the last year had used medica-
tion (ie, medication use in absence of reported professional
consultation).
Table 3 shows associations between reporting medication use
in the last year and sexual behaviour and use of recreational
drugs among all sexually active men.
Medication use was associated with higher levels of sexual activ-
ity, speciﬁcally reporting three or more partners in the last year
and reporting eight or more occasions of sex in the past 4 weeks.
We found strong associations with using the internet to ﬁnd a
partner in the last year, and with paying for sex. Unsafe sex (two
or more partners and no reported condom use in the last year)
Table 3 Prevalence of medicated sex in the last year, and sexual behaviours and recreational drug use associated with its use, among sexually
active men
All
% reporting
medication use 95% CI
Age-adjusted OR
(95% CI)
Adjusted OR*
(95% CI)
Adjusted OR†
(95% CI)
Denominator:
unweighted, weighted
Same-sex identity and experience
Sexual identity
Heterosexual 7.0 (6.2 to 7.9) 1.00 4700, 5838
Any same-sex/other 13.9 (8.2 to 22.7) 2.57 (1.35 to 4.88) 161, 163
At least one same-sex sexual partner, past 5 years
No 6.8 (6.0 to 7.7) 1.00 4685, 5825
Yes 17.9 (11.7 to 26.3) 3.40 (1.99 to 5.82) 180, 183
Sexual behaviour
Had heterosexual sex before 16
No 7.1 (6.1 to 8.1) 1.00 1.00 1.00 3368, 4342
Yes 7.5 (6.1 to 9.2) 1.31 (1.00 to 1.73) 1.30 (0.99 to 1.72) 1.40 (1.05 to 1.88) 1453, 1603
Number of sexual partners in the last year
1 6.2 (5.4 to 7.2) 1.00 1.00 1.00 3568, 4823
2 7.7 (5.3 to 10.9) 1.94 (1.26 to 2.98) 1.86 (1.21 to 2.87) 1.80 (1.13 to 2.85) 539, 512
3+ 14.4 (11.4 to 18.0) 4.44 (3.12 to 6.32) 3.92 (2.73 to 5.63) 3.63 (2.47 to 5.34) 719, 628
Number of occasions of sex, past 4 weeks
0 5.0 (3.6 to 6.9) 1.00 1.00 1.00 1030, 1184
1–3 8.0 (6.6 to 9.6) 1.81 (1.20 to 2.72) 1.77 (1.17 to 2.66) 2.01 (1.31 to 3.09) 1617, 2155
4–7 6.9 (5.4 to 8.8) 1.79 (1.13 to 2.83) 1.74 (1.09 to 2.77) 1.85 (1.13 to 3.04) 1031, 1355
8+ 7.2 (5.5 to 9.3) 2.22 (1.38 to 3.56) 2.13 (1.33 to 3.43) 2.76 (1.66 to 4.59) 1004, 1104
Masturbation in the last month
No 6.6 (5.3 to 8.2) 1.00 1.00 1.00 1308, 1842
Yes 7.4 (6.4 to 8.6) 1.74 (1.28 to 2.37) 1.65 (1.21 to 2.25) 1.45 (1.06 to 2.00) 3545, 4152
Used internet to find sexual partner in past 12 months
No 6.5 (5.7 to 7.4) 1.00 1.00 1.00 4512, 5683
Yes 18.9 (14.2 to 24.6) 4.70 (3.21 to 6.87) 4.00 (2.74 to 5.84) 3.63 (2.36 to 5.58) 352, 323
Paid for sex in the last year
No 6.9 (6.1 to 7.8) 1.00 1.00 1.00 4798, 5929
Yes 28.7 (18.1 to 42.2) 5.67 (2.90 to 11.08) 5.18 (2.55 to 10.50) 5.22 (2.29 to 11.88) 66, 78
2+ partners without using a condom, last year
No 6.4 (5.6 to 7.3) 1.00 1.00 1.00 4162, 5372
Yes 15.2 (11.9 to 19.2) 4.62 (3.25 to 6.56) 4.30 (3.03 to 6.12) 4.06 (2.80 to 5.90) 609, 537
Diagnosed with an STI, last year
No 6.9 (6.1 to 7.9) 1.00 1.00 1.00 4755, 5895
Yes 22.4 (13.0 to 35.8) 7.81 (3.92 to 15.57) 6.52 (3.15 to 13.47) 5.02 (2.31 to 10.93) 72, 63
Recreational drug taking
Ever taken recreational drugs (non-injecting)
No 6.6 (5.6 to 7.7) 1.00 1.00 1.00 2621, 3535
Yes 8.1 (6.8 to 9.5) 2.39 (1.80 to 3.18) 2.26 (1.71 to 3.01) 2.34 (1.72 to 3.18) 2239, 2469
Ever taken amyl nitrates
No 6.7 (5.9 to 7.6) 1.00 1.00 1.00 4456, 5546
Yes 12.8 (9.3 to 17.3) 3.19 (2.15 to 4.74) 2.75 (1.83 to 4.11) 2.60 (1.63 to 4.17) 404, 458
All participants have had at least one sexual partner in the last year.
*Adjusted for age and same-sex partnership in the past 5 years.
†Adjusted for age, at least one same-sex sexual partner in the past 5 years and reporting erectile difficulties.
STI, sexually transmitted infection.
36 Mitchell KR, et al. Sex Transm Infect 2016;92:32–38. doi:10.1136/sextrans-2015-052094
Epidemiology
and STI diagnosis in the past 5 years were also associated with
medication use. After controlling for same-sex behaviour and
reporting of ED, the associations between medication use and
these variables remained signiﬁcant, although most associations
were slightly attenuated. Same-sex behaviour and ever use of recre-
ational drugs such as amyl nitrates were associated with medication
use, although we found signiﬁcant interactions with reporting ED,
indicating no association with same-sex behaviour and ever use of
recreational drugs in men reporting ED.
DISCUSSION
We found that ever use of medication to assist sexual perform-
ance was much more common among men than women; men
were over six times more likely to report ever having medicated
sex (12.9% vs 1.9%). Although women reporting medicated sex
tended to be younger and men to be older, ever use of medica-
tion was associated with recent use of other drugs (alcohol,
cigarettes, recreational drugs), recent unsafe sex, same-sex sex
and low overall sexual function in both genders. Use of medica-
tion in the last year is higher among men reporting ED, 28.4%,
compared with 4.1% among men without difﬁculties, but at a
population level, the proportion of medication users who do
and do not report ED is similar. We found that recent use of
medication increased with age in both groups of men, but low
interest in sex was only associated with medication use in men
without ED. Among men, medicated sex in the last year was
associated with higher levels of sexual activity and a range of
risk-related behaviours, and these associations remained after
controlling for same-sex sex and reporting ED in the last year.
Same-sex experience, as well as ever use of recreational drugs
such as amyl nitrates, was signiﬁcantly associated with medica-
tion use, but not in men reporting ED.
The strength of this study is that it is population-based, and
provides, to our knowledge, the ﬁrst generalisable estimates of
medication use to assist sexual performance among British men
and women. It augments studies of high-risk groups by estab-
lishing the strength of associations with key demographic,
health and sexual behaviour variables at a population level.
A limitation is that our outcome measure did not differentiate
between formal and informal use; nor did it establish the type
of medication most recently used. The question used the word
‘medicine’, and speciﬁed Viagra as an example, thereby strongly
guiding participants towards medical rather than recreational
drugs and towards erectile-dysfunction medication in particular.
It, therefore, seems unlikely that many participants included rec-
reational drugs such as amyl nitrates in their answers, particu-
larly since, in a separate question few participants reported ever
using them (table 3). Our ﬁnding of signiﬁcantly higher preva-
lence of medication use among men with ED compared with
men without strongly suggests that erectile-dysfunction medica-
tion was commonly reported. However, the outcome measure is
harder to interpret with respect to women because much less is
known about the types of medication commonly used by them.
Our data are preliminary, and provide impetus for further
research to explore medication use in women. The cross-
sectional nature of the data means that it is not possible to ascer-
tain the extent to which medication use facilitates risky behav-
iour or simply coincides with it.26 Finally, questions about
sexual behaviour are sensitive, and use of medication might be
prone to under-reporting. We sought to minimise this bias by
the use of CASI.24
The gender difference in recent use of medication to assist
sexual performance likely reﬂects the greater efﬁcacy, wider avail-
ability and heavier marketing of medication for men relative
to women. There is also perhaps a greater societal acceptance of
pharmacological enhancement by men, concomitant with a
greater pressure on men to demonstrate potency. The data suggest
that the association with unsafe sex and STI diagnosis found for
informal and recreational use of medication in selected high-risk
populations7 10 23 is also evident at a population level, and for
women as well as men. We found that associations with unsafe sex
and high levels of sexual activity in men remained after controlling
for same-sex behaviour, suggesting that the association between
medicated sex and sexual risk is not restricted to those practicing
same-sex sex. These ﬁndings suggest that medication use should
be addressed in STI risk-reduction interventions; those targeting
high-risk groups and those operating at a population level. In this
study, over one in ﬁve men diagnosed with an STI in the last year
also reported using medication, which suggests that STI diagnosis
and treatment consultations would be an opportune moment for
clinicians to discuss medication use with their patients.
In men without ED, the association between medication use
and high levels of sexual activity on one hand, and low interest in
sex on the other, seems paradoxical. Previous work sheds light
on this apparent contradiction. Survey research shows an associ-
ation between informal use of PDE-5 inhibitors and low erectile
conﬁdence,15 27 and suggests that lack of sexual conﬁdence is a
common reason for use.8 Qualitative research suggests that infor-
mal medication use among highly sexually active homosexual
men may be an attempt to mask a lack of sexual conﬁdence and
self-esteem3 or to mask low desire. It has also been suggested that
informal users of PDE-5 inhibitors may develop unreasonable
expectations of their erectile performance.15 Although the litera-
ture to date is largely focused on PDE-5 inhibitors, the risk that
medication use leads to increasing dependence and decreasing
conﬁdence in one’s own abilities to respond sexually is relevant
to medical enhancement in general.
Our prevalence estimate of 14% among older men (aged 55–74)
is identical to that estimated from a US probability sample
survey of 3000 older adults (aged 57–85), which similarly asked
participants about their use of ‘medication or supplements to
improve sexual function’ in the last year.28 In addition, we
found that 18% of men reporting same-sex experience in the
past 5 years also reported performance-enhancing medication
use in the last year, which is within the range of between 3%
and 32% reported in a recent review of 11 studies of MSM.23
Primary care providers are accustomed to prescribing PDE-5
inhibitors for erectile dysfunction, but may not be aware of
medication use in their other patients. Our data suggest that
around 13% of their sexually-active male patients and 2% of
their sexually-active female patients may have used medication
to assist their sexual performance; about 4% of their male
patients will be using medication for reasons other than ED,
and 14% of their patients with ED who did not seek help in the
last year will nonetheless be using medication. Where primary
care and sexual health providers are aware of their patients’ use
of medication, they can educate them about the risk of side
effects, the implications for their partner and the potential for
drug interactions. They may also be able to challenge beliefs
that sex should be perfect and that medicine is required to reach
perfection.19 21 Such discussions could be framed by the wider
context of a dramatic rise in lifestyle drugs to assist functioning
in general.1 There may be a need for a public health campaign
targeting men in the general population that encourages indivi-
duals to seek professional advice before taking medication.
This paper is among the ﬁrst to address the evidence gap in
our understanding of medicated sex at a population level. There
is a need for further work to identify the range of medication in
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use, particularly among women. Qualitative research is also
required to further understand the direction of causation between
sexual risk taking and medication use. As medications become
easier to access without prescription, it will be important to track
how the association with risk varies with source of purchase. The
scale of the phenomenon suggests that efforts to understand it
should no longer be conﬁned to studies of high-risk populations.
Key messages
▸ Ever use of medication to assist sexual performance is
reasonably common in Britain, more so in men than women.
▸ It is associated with using other drugs, higher levels of
sexual activity and unsafe sex in both women and men.
▸ In men, associations with high-risk behaviour persist after
adjusting for same-sex behaviour, suggesting the association
with high-risk is not restricted to those practicing same-sex sex.
▸ In men without erectile difﬁculties, medication use is
associated with higher levels of sexual activity and also low
interest in sex. This paradox is perhaps explained by low
sexual conﬁdence.
▸ Because medication is increasingly easy to access without
prescription, there is a need for better professional and
patient education on this phenomenon.
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